title: Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.
abstract: OBJECTIVE
  We examined patients with advanced nonsquamous, non-small cell lung cancer (NSCLC) to evaluate epidermal growth factor receptor (EGFR) mutation status and serum C-reactive protein (CRP) for their associations with response to gefitinib therapy and for prognostic impacts.
  
  
  METHODS
  Serum levels of CRP from 79 Japanese patients with advanced nonsquamous NSCLC were measured before the start of gefitinib. We used the peptic nucleic acid-locked nucleic acid clamp method to determine their EGFR somatic mutation status. We evaluated the relationship between each independent clinicopathological variable and the response to gefitinib therapy and the risk factors associated with prognosis.
  
  
  RESULTS
  Having CRP-positive serum and having wild-type EGFR were both independent negative predictive factors for the response to gefitinib treatment by multivariate logistic regression model analysis. Having CRP-positive serum and having wild-type EGFR were significant independent negative prognostic factors for survival based on multivariate analysis.
  
  
  CONCLUSIONS
  Having CRP-positive serum predicted a lack of response to gefitinib therapy independent of EGFR mutational status. Both CRP-positive serum and wild-type EGFR were independent poor prognostic factors in patients with nonsquamous NSCLC who received gefitinib therapy.
authors: Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan. masago@kuhp.kyoto-u.ac.jp
authors: Katsuhiro
authors: K
authors: Masago
authors: Shiro
authors: S
authors: Fujita
authors: Yosuke
authors: Y
authors: Togashi
authors: Young Hak
authors: YH
authors: Kim
authors: Yukimasa
authors: Y
authors: Hatachi
authors: Akiko
authors: A
authors: Fukuhara
authors: Hiroki
authors: H
authors: Nagai
authors: Kaoru
authors: K
authors: Irisa
authors: Yuichi
authors: Y
authors: Sakamori
authors: Chiyuki
authors: C
authors: Okuda
authors: Tadashi
authors: T
authors: Mio
authors: Michiaki
authors: M
authors: Mishima
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis* / Q000276:immunology; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D002097:C-Reactive Protein; D066246:ErbB Receptors; D000077156:Gefitinib